

# Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation

NCT05145283

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 2
<b>Sponsor</b>	University Hospital, Basel, Switzerland
<b>Enrollment</b>	250 participants

## Key Eligibility Criteria

---

### Inclusion (2)

- Informed consent as documented by signature
- Severe AS and scheduled for transfemoral TAVI

### Exclusion (15)

- Contraindications to the class of drugs under study (C1INH), e.g., known hypersensitivity or allergy to class of drugs or the investigational product
- History of allergy to rabbits (as rhC1INH is derived from the breast milk of transgenic rabbits)
- Women who are pregnant or breast feeding
- Hemodynamic instability requiring emergency TAVI
- Valve-in-valve procedure
- ... and 10 more (see full listing online)

## Locations (2 total)

---

University Hospital Basel, Division of Internal Medicine, Basel, Switzerland  
Städtspital Triemli Zürich, Division of Cardiology, Zurich, Switzerland